Tudor Investment Corp ET AL Has $899,000 Holdings in 10x Genomics $TXG

by · The Cerbat Gem

Tudor Investment Corp ET AL increased its stake in 10x Genomics (NASDAQ:TXG – Free Report) by 135.2% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 76,909 shares of the company’s stock after purchasing an additional 44,206 shares during the quarter. Tudor Investment Corp ET AL’s holdings in 10x Genomics were worth $899,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Arizona State Retirement System lifted its holdings in 10x Genomics by 3.0% during the 3rd quarter. Arizona State Retirement System now owns 29,586 shares of the company’s stock valued at $346,000 after purchasing an additional 872 shares during the last quarter. Versant Capital Management Inc lifted its holdings in 10x Genomics by 3.3% during the 3rd quarter. Versant Capital Management Inc now owns 29,364 shares of the company’s stock valued at $343,000 after purchasing an additional 945 shares during the last quarter. True Wealth Design LLC lifted its holdings in 10x Genomics by 26.4% during the 3rd quarter. True Wealth Design LLC now owns 4,534 shares of the company’s stock valued at $53,000 after purchasing an additional 948 shares during the last quarter. Kera Capital Partners Inc. lifted its holdings in 10x Genomics by 4.0% during the 3rd quarter. Kera Capital Partners Inc. now owns 32,269 shares of the company’s stock valued at $377,000 after purchasing an additional 1,251 shares during the last quarter. Finally, Axxcess Wealth Management LLC increased its position in 10x Genomics by 10.1% during the 3rd quarter. Axxcess Wealth Management LLC now owns 15,045 shares of the company’s stock worth $176,000 after buying an additional 1,376 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 10,000 shares of 10x Genomics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $19.13, for a total value of $191,300.00. Following the transaction, the chief executive officer owned 1,177,273 shares in the company, valued at $22,521,232.49. The trade was a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Taich sold 8,968 shares of 10x Genomics stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $166,625.44. Following the completion of the transaction, the chief financial officer owned 288,417 shares in the company, valued at approximately $5,358,787.86. This represents a 3.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 41,426 shares of company stock worth $779,895 over the last 90 days. Insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $24.80 on Wednesday. 10x Genomics has a 52 week low of $7.25 and a 52 week high of $25.29. The stock has a market capitalization of $3.17 billion, a P/E ratio of -70.86 and a beta of 2.17. The stock’s fifty day moving average is $20.26 and its 200 day moving average is $17.80.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The company had revenue of $166.03 million for the quarter, compared to analysts’ expectations of $160.35 million. During the same quarter last year, the business earned ($0.40) earnings per share. 10x Genomics’s revenue was up .6% on a year-over-year basis. Equities research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Barclays increased their price objective on 10x Genomics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday. TD Cowen increased their price objective on 10x Genomics from $18.00 to $19.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. Deutsche Bank Aktiengesellschaft set a $17.00 price objective on 10x Genomics and gave the stock a “hold” rating in a research report on Friday, February 13th. Leerink Partners lowered their price objective on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 27th. Finally, William Blair upgraded 10x Genomics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 31st. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $19.46.

Get Our Latest Stock Analysis on TXG

10x Genomics Profile

(Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.

Read More

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).